A drug being developed by Teva Pharmaceuticals and Sanofi for inflammation has shown positive results in a Phase 2b clinical trial for ulcerative colitis and Crohn’s disease. The drug, duvakitug, targets a protein called TL1A to reduce inflammation associated with IBD. Results showed higher rates of remission and response compared to placebo, with good safety profiles. Sanofi plans to lead a larger Phase 3 study following these encouraging results. Analysts view the data as compelling compared to competitor drugs targeting TL1A. The companies are now discussing the next steps and potential regulatory approval for Phase 3 trials.
Source link
Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug
